Organ On A Chip Market is Expected to be Flourished by Growing Demand for Alternate Testing Methods1/22/2024 Organ-on-a-chip is an innovative cell culture platform that simulates the activities, mechanics and physiological response of entire organs and organ systems such as the lung, heart, liver, intestine, kidney and blood-brain barrier in a microfluidic cell culture chip format. These microfluidic cell culture devices integrate microfabricated channels and membranes on which cells are cultured. Under dynamic culture conditions, organ-on-chip technology demonstrates significant improvement over conventional cell culture models to better mimic the complex organ-level activities and responses of living organs. The main applications of organ-on-a-chip models are drug screening and development, disease models development, basic research studying organ-level functions and toxicity screening.
The global Organ On A Chip Market is estimated to be valued at US$ 228.24 Mn in 2023 and is expected to exhibit a CAGR of 3.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market Dynamics: Growing demand for alternate testing methods is expected to drive the market growth over the forecast period. Organ-on-a-chip offers significant advantages over traditional animal models by mimicking human physiology at an organ and whole-body level in a microfluidic cell culture chip format. This makes organ-on-a-chip a highly promising tool for drug screening, disease modeling and basic research studying organ functions. Additionally, growing pharmaceutical R&D investments and rising demand for personalized medicine is also fueling the adoption of organ-on-a-chip technologies. However, high costs associated with organ-on-a-chip development and commercialization may hinder market growth during initial years. Segment Analysis The organ on a chip market can be segmented based on type, application, and end user. Based on type, the market is segmented into liver, heart, lung and other types. Among these, the liver chip segment dominates the market and is estimated to account for over 30% share in 2023. This is because liver chips help understand drug metabolism and toxicity in a realistic 3D microenvironment. PEST Analysis Political: Regulatory policies support the organ on a chip technology for drug development and testing. The policymakers encourage reducing animal testing. Economic: The rising R&D investments by pharmaceutical companies and growing focus on developing alternatives to animal testing provide a conducive environment for the market growth. Social: Increasing awareness about humane treatment of animals boosts the adoption of organ chips for medical research over animals. Technological: Advancements in microfabrication techniques, 3D cell culture methods and microfluidics have enabled the development of multi-organ chip systems closely mimicking human physiology. Key Takeaways The Global Organ On A Chip Market Size is estimated to be valued at US$ 228.24 Mn in 2023 and is expected to exhibit a CAGR of 3.1% over the forecast period 2023 to 2030. Regional analysis related content comprises: Regional analysis shows that North America dominates the organ on a chip market currently with over 35% revenue share in 2023. This is majorly driven by presence of key market players and growing adoption of organ chips in pharmaceutical and biotechnology companies for preclinical research. Asia Pacific region is projected to grow at the highest CAGR during the forecast period. This fast growth can be attributed to increasing government initiatives for developing alternatives to animal testing, rising pharmaceutical R&D expenditure and growing biotechnology industry in major countries like China, India and South Korea. Key players related content comprises: Key players operating in the organ on a chip market includes Emulate, Inc., CN Bio Innovations, MIMETAS BV, HUREL Corporation, AxoSim, Inc., Kirkstall and Nortis Bio. Emulate, Inc. is currently dominating the market owing to its diverse organ chip portfolio including liver, heart, lung, gut, kidney and tumor models catering to varied end-use applications. MIMETAS BV is another leading player focusing on developing microfluidic multi-organ systems for modeling disease pathology and screening drug toxicity. Get more insights on this topic: https://www.rapidwebwire.com/organ-on-a-chip-market-demand/ Explore more trending article: https://www.dailyprbulletin.com/organ-on-a-chip-market-size/ Check below trending articles: https://www.marketwebjournal.com/organ-on-a-chip-market-insights/
0 Comments
Leave a Reply. |
NaufanNothing interesting. |